

PI Major Mutations:	None
PI Accessory Mutations:	None
PR Other Mutations:	I13V ^{100%} _{cons=2,371} • I15V ^{0-100%, 1-100%} _{cons=2,387} • E35D ^{100%} _{cons=1,111} • M36I ^{100%} _{cons=1,111} • R41K ^{100%} _{cons=1,701} • R57K ^{100%} _{cons=1,201} • L63P ^{100%} _{cons=1,791} • H69K ^{100%} _{cons=1,711} • L89M ^{100%} _{cons=1,811}
Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:	None
NNRTI Mutations:	Y181YC ^{0-100%, 0-100%} _{cons=1,311}
RT Other Mutations:	E6N ^{100%} _{cons=2,311} • K20KR ^{0-100%, 0-100%} _{cons=2,311} • V35T ^{100%} _{cons=1,111} • T33R ^{100%} _{cons=2,311} • V60V ^{0-100%, 1-100%} _{cons=2,311} • D121H ^{100%} _{cons=1,111} • K122E ^{100%} _{cons=1,111} • I135IT ^{0-100%, 1-100%} _{cons=1,111} • K166Q ^{100%} _{cons=1,111} • Q174K ^{100%} _{cons=1,111} • D177E ^{100%} _{cons=1,111} • V179V ^{0-100%, 1-100%} _{cons=1,111} • T200TA ^{0-100%, 1-100%} _{cons=1,111} • I202V ^{100%} _{cons=1,111} • Q207A ^{100%} _{cons=1,111} • R211K ^{100%} _{cons=1,111} • V245Q ^{100%} _{cons=1,111}
Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible
Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Potential Low-Level Resistance
efavirenz (EFV)	Intermediate Resistance
etravirine (ETR)	Intermediate Resistance
nevirapine (NVP)	High-Level Resistance
rilpivirine (RPV)	Intermediate Resistance

RT comments
NNRTI
<ul style="list-style-type: none">Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. It does not significantly reduce DOR susceptibility.
Other
<ul style="list-style-type: none">V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

[Download CSV](#)

Rule	DOR ⬇	EFV ⬇	ETR ⬇	NVP ⬇	RPV ⬇
<u>Y181YC</u>	10	30	30	60	45